Sacubitril/Valsartan – Entresto®
Drug Class – Angiotensin II Receptor Antagonist/Neprilysin Inhibitor (ARNI)
Mechanism of Action – Valsartan is a competitive antagonist of the angiotensin II receptor which is responsible for the effects of angiotensin II. Sacubitril is a prodrug that inhibits neprilysin. Neprilysin is enzyme responsible for the metabolism of natriuretic peptides
Dosage Forms – Oral tablet (Sacubitril/Valsartan) 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg
Dosing – Patients on a low dose of ACEI/ARB or not previously on an ACEI/ARB start at 24 mg/26 mg po BID. Patients already on moderate or high dose of ACEI/ARB can start at 40 mg/51 mg po BID. You can titrate every 2 to 4 weeks as tolerated
Indications
1.Heart failure with reduced ejection (HFrEF)
Sacubitril/Valsartan – Entresto®
Dosage adjustment
•Dosage adjustment is required in hepatic impairment
•Dosage adjustment is required in renal impairment
Contraindications
•Hypersensitivity to any component
•History of angioedema
•Concomitant use with ACEIs
•Concomitant use with aliskiren
Warnings
•Pregnancy
Pregnancy
•Contraindicated in pregnancy
•Avoid use in breastfeeding
Sacubitril/Valsartan – Entresto®
Drug Interactions
•ACEIs/Aliskiren
•NSAIDs
•Diuretics
•Potassium supplements
Adverse Effects
•Adverse reactions occurring ≥ 5% are hypotension, hyperkalemia, cough, dizziness, and renal failure
Monitoring Parameters
•S/S of heart failure – ability to perform ADL
•BP, renal function, potassium, weight
Therapeutic Pearls
•BNP vs. NT-pro-BNP
•When switching from an ACEI, sacubitril/valsartan is started at least 36 hours after the last dose of ACEI
Sacubitril/Valsartan – Entresto®
Drug Class – Angiotensin II Receptor Antagonist/Neprilysin Inhibitor (ARNI)
Mechanism of Action – Valsartan is a competitive antagonist of the angiotensin II receptor which is responsible for the effects of angiotensin II. Sacubitril is a prodrug that inhibits neprilysin. Neprilysin is enzyme responsible for the metabolism of natriuretic peptides
Dosage Forms – Oral tablet (Sacubitril/Valsartan) 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg
Dosing – Patients on a low dose of ACEI/ARB or not previously on an ACEI/ARB start at 24 mg/26 mg po BID. Patients already on moderate or high dose of ACEI/ARB can start at 40 mg/51 mg po BID. You can titrate every 2 to 4 weeks as tolerated
Indications
1.Heart failure with reduced ejection (HFrEF)
Sacubitril/Valsartan – Entresto®
Dosage adjustment
•Dosage adjustment is required in hepatic impairment
•Dosage adjustment is required in renal impairment
Contraindications
•Hypersensitivity to any component
•History of angioedema
•Concomitant use with ACEIs
•Concomitant use with aliskiren
Warnings
•Pregnancy
Pregnancy
•Contraindicated in pregnancy
•Avoid use in breastfeeding
Sacubitril/Valsartan – Entresto®
Drug Interactions
•ACEIs/Aliskiren
•NSAIDs
•Diuretics
•Potassium supplements
Adverse Effects
•Adverse reactions occurring ≥ 5% are hypotension, hyperkalemia, cough, dizziness, and renal failure
Monitoring Parameters
•S/S of heart failure – ability to perform ADL
•BP, renal function, potassium, weight
Therapeutic Pearls
•BNP vs. NT-pro-BNP
•When switching from an ACEI, sacubitril/valsartan is started at least 36 hours after the last dose of ACEI
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.